Project Grant R01GM166611
Award Date 9/15/26
Completion Date 8/31/30
Dollars Obligated $1.3M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Worcester, MA 01655, USA
Similar Awards
- The National Institute of General Medical Sciences awarded the Board of Regents of the University of Nebraska $422,125 on July 15, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support research on chromatin remodeling mechanisms across scales. The award funds investigation into how BAF, an ATP-dependent nucleosome remodeler, partners with distinct chromatin regulatory mechanisms to establish cell type-specific gene expression programs during development and...
- The National Institute of General Medical Sciences awarded the University of Massachusetts Medical School $460,625 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop machine learning methods that model cis- and trans-regulatory drivers of chromatin accessibility from single-cell multiomic datasets. Over the five-year period of performance through May 31, 2031, the recipient will create machine learning approaches that simultaneously account...
- The National Institute of Neurological Disorders and Stroke awarded the University of Massachusetts Medical School $167,500 on July 14, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to determine biochemical roles for DPF1, DPF3, and PHF10 subunits in mammalian BAF ATP-dependent chromatin remodeling complexes. The research addresses molecular functions of these proteins, which are associated with neurodevelopmental disorders...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc., $144,035 on September 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research dissecting transcription factor-mediated chromatin remodeling complex activities in human cancer. The funded work integrates biochemistry, structural biology, functional genomics, and chemical biology approaches to define how BAF (mammalian SWI/SNF) chromatin remodeling complexes are recruited by transcription...
- The National Institute of General Medical Sciences awarded Beth Israel Deconess Medical Center, Inc. $158,600 on January 23, 2027, under the Biomedical Research and Research Training program (CFDA 93.859) to conduct single-molecule dissection of hypomethylation-driven genome instability. The research combines technology development with mechanistic chromatin biology to address how global DNA hypomethylation—an early epigenetic alteration in human cancer—drives chromosomal instability and DNA...
- The National Institute of General Medical Sciences awarded Oklahoma Medical Research Foundation $468,875 on September 4, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate the role of SWI/SNF chromatin remodeling complexes in germ line transcription and nuclear organization during meiosis. The funded research addresses errors in homologous chromosome segregation during meiosis, which are the leading cause of birth defects and spontaneous pregnancy...
- The National Institute of General Medical Sciences awarded University of Massachusetts Boston $249,000 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate the functional consequences of evolutionary innovation in histone H2A repertoires. The research uses evolutionary innovations in eukaryotic histone proteins to examine how histone repertoires have undergone lineage-specific changes and what selective advantages these changes confer....
- The National Cancer Institute, a division of the National Institutes of Health under the Department of Health and Human Services, awarded $134,000 to the University of Massachusetts Medical School on September 3, 2026, under the Cancer Biology Research program (CFDA 93.396). The recipient will conduct research employing genetically engineered mouse models to elucidate mechanisms by which loss of CAMK2B (calcium/calmodulin-dependent protein kinase II beta) promotes metastasis and immune...
- The National Cancer Institute awarded the University of Massachusetts Medical School $167,500 on May 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop and apply a novel sequencing method for mapping 3-methylcytidine (M3C) modifications in messenger RNA at single-nucleotide resolution. The award funds development of HARP-seq, a highly sensitive technique integrating chemical labeling, enrichment strategies, high-throughput sequencing, and bioinformatics to characterize...
- The National Cancer Institute awarded the University of Massachusetts Medical School $136,840 on December 1, 2025, under the Cancer Research Manpower program (CFDA 93.398) to investigate replication gap suppression in chemoresistant BRCA mutant cancers. The award funds research into the factors contributing to chemoresistance in BRCA1 and BRCA2 mutant hereditary breast and ovarian cancers. The work addresses a critical clinical problem: tumors frequently develop resistance to current...